Part of the University of Oxford, the Jenner Institute brings together investigators who are designing and developing vaccines to generate an exceptional breadth of scientific know-how and critical mass.
We are very proud of Mehreen Datoo, a Jenner Institute Clinical research fellow who has been named on the TIME100 Next list for her work on progressing the R21/Matrix-M malaria vaccine. The vaccine, developed by the Jenner Institute, University of Oxford, was recommended for use by the World Health Organization and started roll-out in July this year. The TIME100 Next list spotlights 100 rising stars who are shaping the future of business, entertainment, sports, politics, science, health and more. Congratulations Mehreen! 🌟
#malaria#vaccine#R21#TIME100https://lnkd.in/efx6cWyQ
The Hill Group at the Jenner Institute, Nuffield Department of Medicine is seeking a Programme Manager, with responsibility for providing management support to a range of pre-clinical and translational projects led by Professor Hill.
The group’s translational activity is underpinned by a strong programme of preclinical work, seeking to identify new vaccine targets, and to design and validate future generations of vaccines. Previously, our principal focus has been upon the development of malaria vaccines using replication-deficient viral vector platforms. More recently, we have developed a virus-like particle approach, which is currently undergoing clinical evaluation. For more information, please visit: https://lnkd.in/etJSuwck
The main responsibilities of this role will be to undertake the financial management of the Hill group portfolio of pre-clinical and translational grant funding including approving requisitions and financial reporting, as well as being responsible for the strategic management of the novel Rvx21 clinical trials in locations such as the UK, Thailand and Indonesia, including financial management, coordination of sites, regulatory approvals and overall Project coordination.
For more information on this exciting opportunity, please see the link below;
https://lnkd.in/ePe_cp_S#programmemanager#malariavaccine#oxforduniversity#wearehiring
Happy to share a review that we recently got published! This review highlights the significant contributions of the evolving mRNA vaccine technology and its potential applications within the One Health framework. My vision is that in the next 10-15 years, mRNA vaccines shall play a transformative role in combating tick-borne diseases and other arthropod-borne pathogens, which are critical for both human and animal health. The review emphasises the urgent need for ongoing research and innovation to overcome current challenges and enhance the feasibility of these vaccines for broader use.
As we continue to advance technologically, the prospect of utilising mRNA vaccines in veterinary medicine is increasingly promising. These advancements could lead to widespread implementation, delivering substantial public health and environmental benefits, and reinforcing the pivotal role of mRNA vaccines in future human health strategies. Congrats to Elizabeth Gonzalez Cueto and thanks to Prof Jose de la fuente for maintaining an active collaboration. Bill & Melinda Gates FoundationJenner InstituteNuffield Department of Medicine